Galmed Pharmaceuticals Ltd. (GLMD) to Release Earnings on Monday
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) is scheduled to post its quarterly earnings results on Monday, November 6th. Analysts expect Galmed Pharmaceuticals to post earnings of ($0.23) per share for the quarter.
Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative return on equity of 141.13% and a negative net margin of 1,443.98%. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.29 million. On average, analysts expect Galmed Pharmaceuticals to post $-0.96 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Galmed Pharmaceuticals Ltd. (GLMD) opened at 8.27 on Monday. Galmed Pharmaceuticals Ltd. has a 12-month low of $2.78 and a 12-month high of $9.59. The stock’s 50 day moving average price is $8.49 and its 200-day moving average price is $6.82. The firm’s market cap is $101.05 million.
GLMD has been the topic of a number of recent analyst reports. Maxim Group reiterated a “buy” rating and issued a $14.00 price objective (up previously from $9.00) on shares of Galmed Pharmaceuticals in a research report on Monday, July 31st. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Wednesday, August 2nd. HC Wainwright raised their price target on Galmed Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, Seaport Global Securities restated a “buy” rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a research report on Friday, October 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Galmed Pharmaceuticals has an average rating of “Buy” and an average price target of $14.75.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.